The estimated Net Worth of Adelene Q Perkins is at least $4.01 Milione dollars as of 8 September 2023. Ms. Perkins owns over 768,133 units of Infinity Pharmaceuticals stock worth over $31,710 and over the last 18 years she sold INFI stock worth over $2,294,050. In addition, she makes $1,680,860 as Chairman of the Board e Chief Executive Officer at Infinity Pharmaceuticals.
Sign up
Ms. Perkins INFI stock SEC Form 4 insiders trading
Adelene has made over 11 trades of the Infinity Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 768,133 units of INFI stock worth $15,363 on 8 September 2023.
The largest trade she's ever made was exercising 768,133 units of Infinity Pharmaceuticals stock on 8 September 2023 worth over $15,363. On average, Adelene trades about 22,227 units every 80 days since 2006. As of 8 September 2023 she still owns at least 1,585,487 units of Infinity Pharmaceuticals stock.
You can see the complete history of Ms. Perkins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Adelene Perkins biography
Adelene Q. Perkins serves as Chairman of the Board, Chief Executive Officer of the Company. She previously served as our President between October 2008 and January 2017, our Chief Business Officer from October 2008 through December 2009 and our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase® business unit. Ms. Perkins has served on the board of directors for the Biotechnology Industry Organization since 2012; the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2017; Massachusetts General Hospital since 2017; the Massachusetts Biotechnology Council, a not-for-profit organization, since 2014; and Project Hope, a not-for-profit social services company, since 2013. Ms. Perkins was on the board of Padlock Therapeutics, a privately held biotechnology company, from 2015 to 2016 and was treasurer of the Massachusetts Life Sciences Center from 2014 to 2016. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain & Company, a strategy consulting firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.
What is the salary of Adelene Perkins?
As the Chairman of the Board e Chief Executive Officer of Infinity Pharmaceuticals, the total compensation of Adelene Perkins at Infinity Pharmaceuticals is $1,680,860. There are no executives at Infinity Pharmaceuticals getting paid more.
How old is Adelene Perkins?
Adelene Perkins is 60, she's been the Chairman of the Board e Chief Executive Officer of Infinity Pharmaceuticals since 2017. There are 6 older and 10 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.
What's Adelene Perkins's mailing address?
Adelene's mailing address filed with the SEC is 83 LINCOLN ROAD, , WAYLAND, MA, 01778.
Insiders trading at Infinity Pharmaceuticals
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
What does Infinity Pharmaceuticals do?
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
What does Infinity Pharmaceuticals's logo look like?
Complete history of Ms. Perkins stock trades at Bruker Corp e Infinity Pharmaceuticals
Infinity Pharmaceuticals executives and stock owners
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Adelene Perkins,
Chairman of the Board, Chief Executive Officer -
Samuel Agresta,
Director -
Lawrence Bloch,
President, Treasurer -
Adelene Q. Perkins,
Chairman & CEO -
Seth Tasker,
Senior Vice President, Chief Business Officer and Secretary -
Dr. Lawrence E. Bloch,
Pres & Treasurer -
Dr. Robert Ilaria Jr., M.D.,
Chief Medical Officer -
Dr. Stephane Peluso Ph.D.,
Chief Scientific Officer -
Seth A. Tasker,
Sr. VP, Chief Bus. Officer & Sec. -
Michael Venuti,
Independent Director -
Richard Gaynor,
Independent Director -
Anthony Evnin,
Independent Director -
David Beier,
Independent Director -
Norman Selby,
Lead Independent Director -
Seth A. Tasker J.D.,
Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. -
Dr. Jeffery L. Kutok M.D., Ph.D.,
Chairman of Scientific Advisory Board -
Dr. Lawrence E. Bloch J.D., M.D.,
Pres & Treasurer -
Jayne Kauffman,
Sr. Exec. Coordinator -
Rossitza Alargova Ph.D.,
Head of Pharmaceutical Devel. -
Dr. Jeffery L. Kutok,
Chairman of Scientific Advisory Board -
Melissa Hackel,
VP of Fin. -
Michael Kauffman,
Director -
Partners L P/Ilbiotechnolog...,
-
Jeffery Kutok,
Chief Scientific Officer -
Ian F Smith,
Director -
Christopher M Lindblom,
Assistant Treasurer -
Jeffrey Berkowitz,
Director -
Jose Baselga,
Director -
Eric S Lander,
Director -
Thomas J. Jr. Lynch,
Director -
Patrick Pak Tin Lee,
Director -
Medical Co L.P. Rosebay,
10% owner -
Steven H Holtzman,
CEO and Assistant Secretary -
Martin Babler,
Director -
David Roth,
Chief Medical Officer -
Winselow S. Jr. Tucker,
Vice President, Marketing -
Gwen A. Fyfe,
Director -
Joshua Hamermesh,
See Remarks -
Co Beacon,
10% owner -
Winston K.C. Lam,
General Counsel -
Gerald E Quirk,
VP,Cor. Affairs & Gnrl Counsel -
Vito J. Palombella,
Chief Scientific Officer -
Thomas Joseph Burke,
Assistant Treasurer -
Harry F Jr Hixson,
Director -
Vicki L Sato,
Director -
Jeffrey K Tong,
VP, Cor. & Product Development -
Herm Rosenman,
Director -
Arnold J Levine,
Director -
James B Tananbaum,
Director -
D Ronald Daniel,
Director -
Franklin Moss,
Director -
William C Jr Bertrand,
General Counsel -
Sujay Kango,
-
Partners L P/Ilbiotechnolog...,
-
Stephane Peluso,
Chief Scientific Officer -
Robert Jr. Ilaria,
Chief Medical Officer -
Brian Schwartz,